Publications

Basic Research Articles in Refereed Journals:

• Young PP, Mendelson CR. A CRE-like element plays an essential role in camp regulation of human SP-A2 gene in alveolar type II cells. Am J Physiol 1996; 271 :L287-99. PMID: 8770068
• Young PP, Mendelson CR. A GT box element is essential for basal and cyclic AMP regulation of the human SP-A2 gene in alveolar type II cells; evidence for binding of lung nuclear factors distinct from Sp1. Mol Endocrinol 1997; 11:1082-1093 PMID: 9212056
• Mendelson CR, Gao E, Young PP, Michael LF, Alcorn JL. Transcriptional regulation of the surfactant protein A (SP-A) gene in fetal lung (review). Chest 1997; 11:96S-106S. PMID: 9212056
• Mendelson CR, Gao E, Li J, Young PP, Michael, LF, Alcorn, JL. Regulation of expression of surfactant protein-A. Biochimica et Biophysica Acta. 1998; 1408(2-3):132-49 PMID: 9813283
• Mendelson CR, Michael LF, Young PP, Li JX, Alcorn JL. Cyclic adenosine monophosphate and glucocorticoid regulation of surfactant protein A gene expression. Endocrinology of the lung: Development and surfactant synthesis, 2000; 59-80.
• Young PP, Hofling A and Sands MS. VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. Proc. Natl. Acad. Sci. USA, 2002; 99: 11951-11956; Track 2. PMID: 12195016
• Young PP, Vogler C, Hofling AA and Sands MS. Biodistribution and efficacy of donor lymphocytes in a murine model of lysosomal storage disease. Molecular Therapy, 2003; 7:52-61. PMID: 12573618 Alcorn JL, Islam K, Young PP, Mendelson CR. Glucocorticoid inhibition of SP-A gene expression in lung
• type II cells is mediated via the TTF-1 binding element. Am. J. Physiol., 2004;286:L767-76. PMID: 14633512
• Young PP, Fantz CR and Sands MS. VEGF opens up the blood brain barrier and promotes survival in nonablative BMT of newborn Twitcher mice. Exp. Neurol.,2004;188:104-114. (*Corresponding author) PMID: 15191807
• Teleron AA, Carlson B and Young PP. Blood donor WBC reduction filters as a source of human peripheral blood-derived endothelial progenitor cells (EPCs). Transfusion, 2005, 45:21-25 PMID: 15647014
• Young PP, Modur V, Teleron AA, Ladenson JH. Enrichment of genes in the aortic intima which are associated with stratified epithelium: implications of underlying biomechanical and barrier properties of the arterial intima. Circulation, 2005,111:2382-90 (*Corresponding author) PMID: 15867175
• Sharpe EE, Teleron AA, Li B, Price J, Sands MS, Alford K, Young PP. The origin and in vivo significance of murine and human culture expanded endothelial progenitor cells (CE-EPCs), Am J Pathol, 2006, 168:1710-21. PMID: 16651636
• Li B, Sharpe EE, Maupin A, Teleron AA, Pyle A, Carmeliet P, Young PP. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at site of tumor neovascularization. FASEB J, 2006, 20:1495-1497. PMID: 16754748
• Young PP, Vaughan DE, Hatzopoulos AKH. Biological properties of endothelial progenitor cells (EPCs) and their potential for cell therapy. Progress in Cardiovascular Dis., 2007, 49:421-9. (*Corresponding author) PMID: 17498522
• Ryzhov S, Solenkova NV, Goldstein AE, Lamparter M, Fleenor T, Young PP, Greelish JP, Byrne JG, Vaughan DE, Biaggioni I, Hatzopoulos AK, Feoktistov I. Role of adenosine receptors in adhesion of endothelial progenitors to cardiac microvascular endothelial cells. Circulation Res.,2008, 102:356-63
• PMID: 18032734
• Devin JK, Vaughan DE, Blevins LS, Chen Q, Covington J, Verity DK, and Young PP. Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults. Growth Hormone and IGF Res., 2008, 18:253-63. PMID: 18166495
• Devin JK and Young PP. The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells. Curr Opin Invest Drug, 2008, 9:983-92. PMID:18729005
• Pyle AL, Li B, Maupin AB, Guzman RJ, Crimmins DL, Olson S, Atkinson JB and Young PP Biomechanical stress induces novel arterial intima-enriched genes: implications for vascular adaptation to stress. Cardiovasc Pathol, 2008, epub. PMID: 19211270
• Pyle AL, Atkinson J, Pozzi A, Eckes B, Davidson JM, Crimmins DL, Reese J and Young PP. Regulation of atheroma-enriched protein, SPRR3, in vascular smooth muscle cells through cyclic strain is dependent on integrin a1b1/collagen interaction. Am J Pathol, 2008, 173:1577-88 PMCID: PMC2570146
• Alfaro MP, Pagni M, Vincent A, Atkinson J, Hill MF, Cates J, Davidson JM, Rottman J, Lee E, and Young PP. A Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc. Natl. Acad. Sci. USA, 2008, 105:18366-71, Track 2. PMID: 19017790
• Li B, Vincent A, Cates J, Brantley-Sieders, D, Polk DB, Young PP. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Research, 2009, 69:338-48. PMID: 19118019
• Barnes SL, Young PP, Miga MI. A novel model-gel-tissue assay analysis for comparing tumor elastic properties to collagen content. Biomechanics and Modeling in Mechanobiology, 2009, 8:337-43. PMID: 19308472
• Young PP, Ardestani S, Li B. Myeloid Cells in Cancer Progression: Unique Subtypes and Their Roles in Tumor Growth, Vascularity, and Host Immune Suppression. Cancer Microenvironment,2010, 4:1-11. PMID: 21505557
• Cates JM, Friedman DB, Seeley EH, Dupont WD, Schwartz HS, Holt GE, Caprioli RM, Young PP. Proteomic analysis of osteogenic sarcoma: association of tumor necrosis factor with poor prognosis. 2010 International J Exp Pathol, 91: 335–349. PMID: 20353421
  Pyle AL and Young PP. Atheromas feel the pressure: biomechanical stress and the progression of atherosclerosis. Am J Pathol, 2010, 177:4-9. PMID: 20558573
• Alfaro MP, Vincent A, Thorne CA, Hong C, Lee E, Young PP. sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. Journal Biological Chemistry, 2010, 285: 35645-35653. PMID: 20826809
• Saraswati S, Alfaro MP, Thorne CA, Atkinson J, Lee E, and Young PP. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One, 2011, 5(11): e15521. PMID: 21170416
  Li B, Pozzi A, and Young PP. TNFα a
• Alfaro MP, Deskins DL, Wallus M, Dasgupta J, Davidson JM, Nanney LB, Guney M, Gannon M, Young PP. A pro-reparative role for connective tissue growth factor in early wound healing. Lab Invest. 2013 Jan;93(1):81-95. PMID: 23212098
• Deskins DL, Bastakoty D, Saraswati S, Shinar A, Holt GE and Young PP. Human Mesenchymal Stem Cells: Identifying assays to predict potency for therapeutic selection. Stem Cells Translational Medicine, 2013 Feb;2(2):151-8. PMID: 23362238
• Ardestani S, Li B, Deskins DL, Wu J, Massion PP, Young PP. Membrane versus Soluble Isoforms of TNF-α Exert Opposing Effects on Tumor Growth and Survival of Tumor-Associated Myeloid Cells.
• Cotton BA, Au BK, Nunez TC, Gunter OL, Robertson A, and Young PP. Predefined massive transfusion protocols are associated with reduction in organ failure and post injury complications. J Trauma, 2009, 66:41-49 PMID: 19131804
• Cotton BA, Dossett LA, Au B, Kaltenbach LA, Nunez TC, Robertson A, and Young PP. Room for performance improvement: provider-related factors associated with poor outcomes in massive transfusion. J Trauma, 2009, 67:1004-12. PMID: 19901661
  Au BK, Dutton WD, Zaydfudim V, Nunez TC, Young PP, Cotton BA. Hyperkalemia following massive transfusion in trauma. J Surgical Sciences, 2009, 157:284-9 PMID:19765727
• Dutton W, Nunez T, Au B, Zaydfudim V, Dossett L, Young PP, Cotton BA. Higher plasma and platelet ratios are associated with a reduction in mortality in non-massively transfused trauma patients. J Trauma,201 1 in press
• Nunez TC, Dutton WD, May AK, Holcomb JB, Young PP, Cotton BA. Emergency department blood transfusion predicts early massive transfusion and early blood component requirement. Transfusion, 2010, 50: 1914–1920. PMID: 20456707
• Cotton BA, Dossett LA, Haut ER, Shafi S, Nunez TC, Au BK, Zaydfudim V, Johnston M, Arbogast P and Young PP. Multicenter Validation of a simplified score to predict massive transfusion in trauma. J Trauma, 2010, 69:S33-37. PMID: 20622617
• Nunez TC, Young PP, Holcomb JB and Cotton BA. Creation, implementation, and maturation of a massive transfusion protocol for the exsanguinating trauma patient. J Trauma, 2010, 68:1498-1 508. PMID: 20539192
• O’Leary MF, Szklarski P, Young PP. Hemolysis of red blood cells after cell washing with different automated technologies: clinical implications in a neonatal cardiac surgery population. Transfusion, 2010, 51:955-60. PMID: 21091957
• Jacobs M, Smith D, Heaton WA, Zantek ND, Good CD, and the PGD Study Group. Detection of bacterial
• contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera
• Detection test. Transfusion, 2011 PMID: 21883265
• Young PP, Cotton BA, Goodnough LT. Transfusion Medicine Resuscitation of Massively Bleeding. Transfusion Medicine Reviews, 2011, 25:293-303. PMID: PMC31 76940
• Gehrie E, Neff At, Ciombor KK, Harris N, Seegmiller AC, Young PP. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis. Transfusion, 2011, 52:4-5. PMID: 22032241.
• Young PP, Cotton BA. A window of opportunity: the aggressive use of plasma in early resuscitation. Transfusion, 2011, Sept;51(9):1880-2. PMID: 21896029.
• Gehrie E, Neff AT, Ciombor KK, Harris N, Seegmiller AC, Young PP. Transfusion medicine illustrated. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis. Transfusion, 2012 Jan;52(1): 4-5. PMID: 22032241
• McClain CM, Hughes J, Andrews JC, Blckburn J, Sephel S, France D, Viele M, Goodnough LT, Young PP. Blood ordering from the operating room: turnaround time as a quality indicator. Transfusion. 2013, 53:41-8. PMID: 22127236
• Gehrie EA, Cates J, Young PP. Blood group A antigen expression on cardiac endothelium is highly individualized: possible implications for transplantations. Cardiovasc Pathol. 2013, 22:251-6. PMID:23290353
Young PP and Booth GS. Response to How I treat transfusional iron overload. [e-Letter], Blood (http://bloodjournal.hematologylibrary.org/content/1 20/18/3657). November 1, 2012. Accessed November 21, 2012.
• Janz DR, Zhao Z, Koyama T, May AK, Bernard GR, Bartarache JA, Young PP and Ware LA. Longer storage duration of red blood cells is associated with an increased risk of acute lung injury in patients with sepsis. Annals of Intensive Care, 2013, 3:33. PMID: 24059842
• Gehrie EA, Nian H and Young PP. Brown recluse spider bite mediated hemolysis: clinical features, a possible role for complement inhibitor therapy and a potential biomarker of venom exposure. PLoS One, 2013, 8:e76558 PMID: 24059842
• Cohen, DA, Johnson, MS, Liang WH, McDaniel HL and Young PP. Clinically significant hemolytic disease of the newborn secondary to passive transfer of anti-D from maternal RhIG. Transfusion 2014, in press
• Gehrie, E. Muranyi A. Walk E. Young PP. Commercially available blood group antibodies may be used to visualize blood group A antigen in paraffin-embedded tissue sections. Arch Pathol Lab Med. 2014. 138:155.
• Oakley FD, Woods M, Arnold S, Young PP. Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type and associated products. Transfusion 2014. In press.
• Young PP and Schafer R. Cell based therapies for cardiac disease: a cellular therapist’s perspective. Transfusion, 2014, in press.
• Whitney GM, Woods MC, France DJ, Deegan RJ, Paroskie A, Baker CS, Booth GS, Young PP, Dmochowski RR, Sandberg W and Pilla MA. Reducing intraoperative red blood cell unit wastage in a large academic medical center. Submitted.
• Books, Book Chapters, Invited Review Articles:
• Mendelson CR, Gao E, Young PP, Michael LF, Alcorn JL. The surfactant protein A gene and its regulation. In Lung Surfactant: Cellular and Molecular Processes. Editor, Seamus E. Rooney, published by R.G. Lardey (Austin, TX), 1999.
• Sverstiuk A and Young PP. Platelet refractoriness. In Transfusion Service. Editor, Gretchen Johns, Publisher Prentice Hall, in press.
• Young PP. Chapter 15: Introduction to blood transfusion therapy. In Medical Laboratory Technology, A Procedure Manual for Routine Diagnostic Tests, 2nd Edition. Editor, Kanai Mukherjee, Publisher McGraw-Hill of India, in press.
• Mukherjee, KL and Young PP. Chapter 16: Collection and processing of blood for transfusion. In Medical Laboratory Technology, A Procedure Manual for Routine Diagnostic Tests, 2nd Edition. Editor, Kanai Mukherjee, Publisher McGraw-Hill of India, 2010.
• Young PP. Chapter 17: Routine laboratory procedures in blood bank. In Medical Laboratory Technology, A Procedure Manual for Routine Diagnostic Tests, 2nd Edition. Editor, Kanai Mukherjee, Publisher McGraw-Hill of India, 2010.
• Young PP. Chapter 18: Blood transfusion services and haemolytic disease of the newborn. In Medical Laboratory Technology, A Procedure Manual for Routine Diagnostic Tests, 2nd Edition. Editor, Kanai Mukherjee, Publisher McGraw-Hill of India, 2010.
• Eichbaum, Q, Booth G, and Young PP. Transfusion Medicine: Quality in Laboratory Diagnosis. Laposata
• M, ed.; 1st ed. New York, NY: Demos Medical, 2012. 1st ed. New York, NY: Demos Medical, 2012.
• 8.. Bastakoty D, Saraswati S and Young PP. Chemicals and stem cells for promoting regeneration. Invited chapter in Chemical Biology in Regenerative Medicine: Bridging Stem Cells and Future Therapies, in press. 2013
• 9. Andrij Sverstiuk and Pampee P. Young. Platelet refractoriness. Invited chapter in: Clinical Laboratory Blood Banking and Transfusion Medicine Practices. Ed. Gretchen Johns, William Zundel, Elizabeth Gockel-Blessing and Lisa Denesiuk. Prentice Hall, 2015. ISBN-10:0130833312

Abstracts and Presentations

Oral Presentations:

• “Characterization of a GT b ox element involved in cAMP-regulated transcription of the SP-A2 gene in pulmonary type II cells.” Oral presentation at annual meeting of American Thoracic Society, Las Vegas, USA, May, 1994
• “Characterization of a GT box and a CRE-like element in the 5’-flanking region of the human surfactant protein A2 gene that mediates basal and cAMP-regulated expression.” Oral Presentation and the annual meeting of The Endocrine Society, Washington, D.C., June, 1995
• “Regulation of surfactant synthesis in human fetal lung: the role of cAMP” oral presentation at annual meeting of American Thoracic Society, New Orleans, USA, May 1996
• “VEGF mediates EPC engraftment in neonatal mice” oral presentation at annual meeting of Academy of Clinical Laboratory Physicians and Scientists, New York, NY, 2002
• “VEGF increases engraftment of bone marrow-derived endothelial progenitor cells into vasculature of newborn mice” 9th Midwest Platelet and Vascular Biology Conference, St. Louis, MO, USA, October 11-13, 2002. (Invited presentation)
• “VEGF opens the neonatal blood brain barrier and enhances cellular therapy” oral presentation at annual meeting of Academy of Clinical Laboratory Physicians and Scientists, Seattle, WA, 2003.
• “Role of VEGF and VEGF receptors in EPC recruitment to site of tumor growth” The 18th Annual Symposium on Advanced Wound Care, San Diego, CA, USA, April 21-24, 2005. (Invited presentation)
• “Early outgrowth EPCs are derived from monocytes” oral presentation Atherosclerosis Thrombosis Vascular Biology, Washington D.C., USA, April, 2005
• “How to promote tumor neovascularization: VEGF and PlGF work together” Emory Pathology Seminars, December, 2005. (Invited presentation)
• 10 . “The role of AIE genes in vascular response to cyclic stress” Pfizer ARA research forum, Salt Lake City, Utah, February, 2006. (Invited presentation)
• 11 . “Optimizing the Trauma Exsanguinations Protocol” oral presentation at American Association of Blood Bank National Meeting, Anaheim, CA, 2007
• 12 . “EPCs, Vascular Leukocytes and TAMs—Is there a common thread?” Clinical Pathology Grand Rounds, Washington University School of Medicine, St. Louis, January, 2008. (Invited presentation)
• 13 . “How TNF promotes tumor growth: Role of myeloi d subpopulations” University of Chicago Medical School Pathology Grand Rounds, April, 2008. (Invited presentation)
• “Damage control hematology: opti mizing trauma exsanguinations protocol” Marian Beard Seminar. University of Louisville Medical School, KY. May, 2008. (Invited presentation)
• Plenary lecture “Mesenchymal stem cells in wound and cardiac repair: lessons from the wnt pathway” at European Tissue Repair Society/Wound Healing Society international joint meeting in Limoges, France, August 20-24, 2009. (Invited presentation)
• 16 . “Role of TNF in cancer progression through the generation of myeloid/endothelial biphenotypic cells”, oral presentation in International Tumor Microenvironment Society/American Association of Cancer Research joint meeting in Versailles, France, October 20-25, 2009. (Invited presentation)
• 17. “Use of rVI Ia in trauma”, RAP session, American Association of Blood Banks, October, 2009, New Orleans, LA. (Invited presentation)
• 18 . “Mesenchymal stem cells as cellular therapy” University of Californi a Medical Center in San Diego. Department of Pathology Grand Rounds. December 14, 2009. (Invited presentation)
• 19. “sFRP2 enhances myocardial repair potential of MSCs by modulating both Wnt and BMP signaling pathways to increase self-renewal and decrease ectopic calcification of the myocardium” Stem Cells World Congress, Jan. 2010, San Francisco, USA. (Invited presentation)
• 20 . “Stem cells and the future of Cell Therapy” Emory University Medical School Pathology Grand Rounds. Feb, 2010. Atlanta, GA. (Invited presentation).
• “How to make a better stem cell” Academy of Clinical Laboratory Physicians and Scientists National Meeting. June, 2010. Nashville, TN (Invited presentation and Ellis Benson Young Investigator awardee)
• “How matrix affects stem cell biology” Vanderbilt Symposium on Basement Membranes in Tissue Development and Regeneration, July 2010, Nashville, TN (Invited presentation)
• “Management of MTPs” Tennessee Association of Blood Banks, June, 2010, Chattanooga, TN. (Invited presentation).
• “Mesenchymal Stem Cells” Tennessee State University Lecture Series in Biological Sciences. September, 2010. Nashville, TN. (Invited presentation)
• “Progenitors in Wound Healing: Repair vs. Regeneration” Plenary talk at International Wound Healing Society Conference., Dallas, Tx. April 2011. (Invited presentation)
  Vein to Vein: Transfusion Service Q uality”, AABB 2011, San Diego, CA (Invited presentation).
  “Organizational quality oversight of the transfusion service”. Invited webinar for U niversity Health Consortium, June 22, 2011. (Invited webinar)
• “Advances in Cardiac Regeneration” AABB, 2012, Boston, MA (Invited presentation)
• “Ethical Issues in the Allocation of Blood and Blood Products”, Ethics Grand Rounds, Vanderbilt, 2012

Patents

• Young PP and Sands MS. Use of endothelial progenitor cells for neonatal gene therapy. Application of patent filed July, 2003.
• Ladenson, J.M., Young, P.P. and Modur, V. Method of assessing the risk of atherosclerosis. US provisional patent application filed April, 2004.
• Lee E, Young PP, Meyers K, Thorne C, and Eid J. Development and therapeutic use of anti-LRP5/6 antibodies that inhibit Wnt signaling. US Patent Application Number 13/460,242. Filed June, 2012
• Lee E and Young PP. Pyrvinium for wound treatment. US Patent Number 13/426,2 10. Filed May 2012